Demographic, hematologic, and graft features of study patients with AML
| UPN . | Age, y . | Sex . | WBC count, × 109/L . | Karyotype . | Genotype . | FAB . | HLA typing (mismatch) . | Donor KIR-L mismatch . | Disease status before NK infusion . | Infused NK cells, ×106/kg) . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 68 | F | 6.2 | 46 XX | NE | M2 | -C group 2 | 2DL1 | Resistant | 3.16 |
| 2 | 66 | M | 0.4 | 46 XY | FLT3 WT | M1 | -C group 2 | 2DL1 | Resistant | 1.34 |
| NPM WT | ||||||||||
| 3 | 65 | M | 51.3 | 46 XY | NE | M1 | -C group 1 | 2DL2/3 | Resistant | 5.00 |
| 4 | 62 | F | 2.4 | 46 XX | FLT3 WT | M1 | -C group 1 | 2DL2/3 | Resistant | 5.00 |
| NPM1WT | ||||||||||
| 5 | 62 | M | 5.25 | Complex | FLT3 WT | sec | -C group 2 | 2DL1 3DL1 | Resistant | 1.11 |
| NPM WT | -Bw4 | |||||||||
| 6 | 59 | F | 4.32 | 46 XX | FLT3 WT | M1 | -C group 2 | 2DL1 | CR | 4.00 |
| NPM WT | ||||||||||
| 7 | 73 | M | 75.0 | 46 XY | FLT3 TKD | M5 | -C group 1 | 2DL2/3 3DL1 | CR | 5.00 |
| -Bw4 | ||||||||||
| 8 | 58 | M | 74.8 | 46 XY | FLT3 WT | M4 | -Bw4 | 3DL1 | CR | 1.81 |
| NPM WT | ||||||||||
| 9 | 69 | M | 25.0 | Complex | FLT3 WT | M1 | -C group 1 | 2DL2/3 | CR | 2.05 |
| NPM WT | ||||||||||
| 10 | 53 | F | 4.1 | 46 XX | NE | M1 | -C group 1 | 2DL2/3 3DL1 | Molecular relapse | 3.89 |
| +8−7 | -Bw4 | |||||||||
| 11 | 67 | M | 2.7 | NE | FLT3 WT | M0 | -C group 1 | 2DL2/3 | CR | 2.74 |
| NPM WT | ||||||||||
| 12 | 61 | M | 2.9 | 46 XX | FLT3 WT | sec | -C group 1 | 2DL2/3 | CR | 2.51 |
| NPM WT | ||||||||||
| 13 | 58 | F | 5.8 | inv(16) | CBFMYH11 | NE | -C group 2 | 2DL1 | Molecular relapse | 1.29 |
| UPN . | Age, y . | Sex . | WBC count, × 109/L . | Karyotype . | Genotype . | FAB . | HLA typing (mismatch) . | Donor KIR-L mismatch . | Disease status before NK infusion . | Infused NK cells, ×106/kg) . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 68 | F | 6.2 | 46 XX | NE | M2 | -C group 2 | 2DL1 | Resistant | 3.16 |
| 2 | 66 | M | 0.4 | 46 XY | FLT3 WT | M1 | -C group 2 | 2DL1 | Resistant | 1.34 |
| NPM WT | ||||||||||
| 3 | 65 | M | 51.3 | 46 XY | NE | M1 | -C group 1 | 2DL2/3 | Resistant | 5.00 |
| 4 | 62 | F | 2.4 | 46 XX | FLT3 WT | M1 | -C group 1 | 2DL2/3 | Resistant | 5.00 |
| NPM1WT | ||||||||||
| 5 | 62 | M | 5.25 | Complex | FLT3 WT | sec | -C group 2 | 2DL1 3DL1 | Resistant | 1.11 |
| NPM WT | -Bw4 | |||||||||
| 6 | 59 | F | 4.32 | 46 XX | FLT3 WT | M1 | -C group 2 | 2DL1 | CR | 4.00 |
| NPM WT | ||||||||||
| 7 | 73 | M | 75.0 | 46 XY | FLT3 TKD | M5 | -C group 1 | 2DL2/3 3DL1 | CR | 5.00 |
| -Bw4 | ||||||||||
| 8 | 58 | M | 74.8 | 46 XY | FLT3 WT | M4 | -Bw4 | 3DL1 | CR | 1.81 |
| NPM WT | ||||||||||
| 9 | 69 | M | 25.0 | Complex | FLT3 WT | M1 | -C group 1 | 2DL2/3 | CR | 2.05 |
| NPM WT | ||||||||||
| 10 | 53 | F | 4.1 | 46 XX | NE | M1 | -C group 1 | 2DL2/3 3DL1 | Molecular relapse | 3.89 |
| +8−7 | -Bw4 | |||||||||
| 11 | 67 | M | 2.7 | NE | FLT3 WT | M0 | -C group 1 | 2DL2/3 | CR | 2.74 |
| NPM WT | ||||||||||
| 12 | 61 | M | 2.9 | 46 XX | FLT3 WT | sec | -C group 1 | 2DL2/3 | CR | 2.51 |
| NPM WT | ||||||||||
| 13 | 58 | F | 5.8 | inv(16) | CBFMYH11 | NE | -C group 2 | 2DL1 | Molecular relapse | 1.29 |
UPN indicates unique patient number; WBC, white blood cell; FAB, French-American-British; KIR-L, killer Ig-like receptor ligand; NK, natural killer; NE, not evaluated; FLT3, FMS-like tyrosine kinase 3; NPM, nucleophosmin; WT, wild type; CR, complete remission; TKD, tyrosine kinase domain; and CBF, core binding factor.